MDIN Continues to Rally

Northstar announces breakthrough new product line and its first product to target the $2.7 billion sports nutrition market
HOLBROOK, N.Y., Nov. 8, 2012 /PRNewswire via COMTEX/ -- Northstar Global Business Services, Inc. (PINK SHEETS: MDIN) today announced it's newest product will target the $2.7 billion annual sports nutrition market with a new stem cell replacement therapy tablet that allows individuals to build muscle many times faster than normal.

The breakthrough product uses a unique blue-green algae extract called Aphanizomenon flos-aquae (AFA), which has been proven to increase the number of free flowing adult stem cells in the human body by as many as several hundred times the norm. Company CEO, Nick Chieco Said, "This product has been researched by us for years now, and we are very excited about getting into retail stores across America along side our proven products, Snorenz� and GoodNight's Sleep�." He went on to say, "The first product in this new line, Stemintense(TM) is so exciting because it is legal, healthy, all natural, has tons of additional benefits like anti-oxidants, and according to clinical trials works better for building muscle then even the most potent steroids!" Fitness enthusiasts often flood their system with proteins, the building blocks of muscle, this product floods your system with actuals cells that can become muscle cells.

Clinical studies have shown the potential of this new supplement to be astounding, and everyone knows that fitness fanatics looking to build muscle and get larger will do, and pay almost anything to achieve their goals. The company's Stemintense(TM) product offers to do that in a safe and healthy way, something no other solution offers. Initially it will hit the shelves as a tablet but a protein shake version is also in the works as well as the licensing of Stemintense(TM) to other major protein shake and bar manufacturers as an additive. Because the product has a higher price point than the company's other products, it offers a much higher net profit margin, almost three times higher. Overall these three strategies aim to achieve 35% to 45% market saturation by 2015. This could represent hundreds of millions in revenue to the company over the three-year period.

The new product line, which Stemintense(TM) is part of is currently made up of four distinct products, which all use stem cell replacement therapy in one form or another. These products target areas of fitness, beauty, anti-aging, first aid, healing, and mental acuity, memory and intelligence. The other three products will be released later this year.

The primary role of adult stem cells in a living organism are to maintain and repair the tissue in which they are found, and the all natural ingredients used here trigger the body to mass produce these cells in different ways. The company states it has always brought new technology in alternative health to the public, and is determined to continue this trend, while taking it to new heights.

About NorthstarNorthstar Global Business Services, Inc. owns and produces alternative healthcare products through its "Medgen" division. Among it's products are the popular "Snorenz�", Painenz�, and "Goodnight's Sleep�" which have sold as many as five million units annually in the past through both direct sales and nationwide retail chains such as Walmart(TM), CVS(TM), and Walgreen's(TM).

This Press Release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company has tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential" and similar expressions. These statements reflect the Company's current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance or achievements to differ materially from those expressed in or implied by such statements. The Company undertakes no obligation to update or advise in the event of any change, addition or alteration to the information catered in this Press Release including such forward-looking statements.

For more information on Stemintense(TM) visit: www.medgeninc.com/stemintenseOr email: shareholders@northstarbb.com